MD, CFPC, FCFP, Family Physician, discusses What is Chronic Obstructive Pulmonary Disease.

People with COPD are vulnerable to small increases in PM2.5, with each 1 μg/m3 rise in long-term exposure linked to a 3.8% ...

Home-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD).

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...

The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a Phase ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Yet thanks to a new hospital-based educational and advocacy initiative for COPD patients, Croswell has been managing well at ...

For COPD patients, the adage holds true: "the first way to get out of a hole is to quit digging one," said Christopher Mosher ...

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

HealthDay News — Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a study published online May 13 in Communications Medicine.

as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD). Nucala stands out as the only approved biologic that has been ...